Illumina Files Additional Patent Infringement Suit Against BGI in the U.S.

Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed a patent infringement suit relating to BGIs CoolMPS sequencing products.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, February 27, 2020
Information
Tags: 
Biotechnology, Health, Genetics, Professional services, Legal, Biotechnology companies, DNA sequencing, Branches of biology, Biology, Illumina, Inc., Microarrays, Complete Genomics, Patent infringement, BGI Group
Geotags: 
United States, California
⚠ generated by AI ↴
Organisation: 
ILLUMINA
Summary
Key Points: 
  • Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed a patent infringement suit relating to BGIs CoolMPS sequencing products.
  • The complaint was filed against BGI Genomics Co., Ltd., BGI Americas Corp., MGI Tech Co., Ltd., MGI Americas, Inc. and Complete Genomics Inc. in the United States District Court for the Northern District of California alleging infringement of three patents: US Patent Nos.
  • Illuminas patent portfolio reflects the incredible innovation of Illuminas employees and the investment of hundreds of millions of dollars that Illumina spends annually on research and development, said Charles Dadswell, SVP and General Counsel for Illumina.
  • Counterparts to these newly asserted patents have been upheld by the U.S. Patent Trial and Appeal Board and the European Patent Office over challenges filed by BGI, Complete Genomics and others.


Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed a patent infringement suit relating to BGI’s “CoolMPS” sequencing products. The complaint was filed against BGI Genomics Co., Ltd., BGI Americas Corp., MGI Tech Co., Ltd., MGI Americas, Inc. and Complete Genomics Inc. in the United States District Court for the Northern District of California alleging infringement of three patents: US Patent Nos. 7,541,444; 7,771,973; and 10,480,025. The complaint seeks, among other things, damages, injunctive relief and attorney fees. The patents cover Illumina’s proprietary sequencing-by-synthesis chemistry.

“BGI has brazenly copied Illumina’s proprietary sequencing chemistry. Illumina’s patent portfolio reflects the incredible innovation of Illumina’s employees and the investment of hundreds of millions of dollars that Illumina spends annually on research and development,” said Charles Dadswell, SVP and General Counsel for Illumina. “We will continue to monitor and defend our intellectual property by appropriate enforcement when our patents are infringed.”

Related patent suits are pending in Denmark, Germany, Sweden, Switzerland, Turkey, the UK and the U.S. Counterparts to these newly asserted patents have been upheld by the U.S. Patent Trial and Appeal Board and the European Patent Office over challenges filed by BGI, Complete Genomics and others.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Copyright: 
Copyright Business Wire 2020